002653.SZ
002653.SZ
CNE100001BC7
HAISCO PHARMA
Loading chart...

Company Profile

Haisco Pharmaceutical Group Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in China. It offers pharmaceutical products in the areas of anesthesia and analgesic, endocrine system, enteral parenteral nutrition, cardiovascular, psychiatric, tumor-related, digestive liver, and other diseases. Haisco Pharmaceutical Group Co., Ltd. has licensing and research collaboration with Eli Lilly and Company to develop medicines across multiple therapeutic areas. The company was formerly known as Xizang Haisco Pharmaceutical Group Co., Ltd. and changed its name to Haisco Pharmaceutical Group Co., Ltd. in March 2016. Haisco Pharmaceutical Group Co., Ltd. was founded in 2000 and is based in Shannan, China.

Related stocks

9926.HK
9926.HK • China
AKESO
109.1 HKD
12.81B USD 1Y -17%
6990.HK
6990.HK • China
SKB BIO
444.6 HKD
13.54B USD 1Y -12.9%
002821.SZ
002821.SZ • China
ASYMCHEM
177.93 CNY
9.64B USD 1Y +56.8%
688578.SS
688578.SS • China
SHANGHAI ALLIST PHARMACEUTICALS
82.5 CNY
5.56B USD 1Y -23%
6821.HK
6821.HK • China
ASYMCHEM
155.1 HKD
7.15B USD 1Y +60.9%
688266.SS
688266.SS • China
SUZHOU ZELGEN BIOPHARMACEUTICAL
104.25 CNY
4.13B USD 1Y -2.2%
688331.SS
688331.SS • China
REMEGEN CO LTD
107.86 CNY
9.11B USD 1Y +4.2%
688428.SS
688428.SS • China
INNOCARE PHARMA LTD
28.12 CNY
7.44B USD 1Y +5.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile
5 Metrics

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
45.5% p.a.
Max Drawdown (5Y)
-39.4%
Sharpe Ratio (5Y)
0.55
Beta Factor
-0.19
Size Class
Large Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 High valuation risk: Avg P/E of 68.6 (Elevated multiple compression risk)
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (45.5% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -55.3% in the extended horizon.
ende